We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

By LabMedica International staff writers
Posted on 25 Nov 2021

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players. More...

Furthermore, the rising prevalence of chronic and infectious diseases such as heart disease, hepatitis, cancer, gastrointestinal, respiratory, and sexually transmitted diseases (STDs) is driving the point of care diagnostics market. These are the latest findings of Valuates Reports (Bangalore, India), a provider of market research reports and industry analysis.

An increase in the number of diabetic cases is expected to drive the growth of the point of care diagnostics market. The adoption of blood glucose monitoring systems is increasing due to factors such as the growing number of diabetic patients, increased patient knowledge of the importance of blood sugar monitoring, and the development of novel monitoring devices by important players. Other key factors likely to drive the growth of the point of care diagnostics market include the rising prevalence of other respiratory illnesses around the world, the shift toward decentralized diagnostics, and improved access to point-of-care devices through online platforms.

Point of care testing can significantly enhance the management of infectious diseases, particularly in underdeveloped nations where prompt medical care is difficult to come by and healthcare infrastructure is lacking. Furthermore, government incentives and grants for the development of new products are accelerating the adoption of improved diagnostic technology for infectious diseases. People in undeveloped and developing countries can now afford these tests thanks to such initiatives. During the forecast period, factors such as the increasing number of clinics implementing point of care testing for the rapid identification of infectious diseases are expected to fuel market growth.

Nanotechnology integration in rapid diagnostics is also expected to drive the growth of the point of care diagnostics market. With technological improvements, it is critical that high-quality healthcare management be implemented for fast patient care. Nanotechnology has allowed scientists to investigate a wide range of healthcare applications. Product demand will be boosted further by the production of nanotechnology-based point of care diagnostics. The COVID-19 outbreak is expected to further propel the growth of the point of care diagnostics market as the increasing usage of point of care tests that can rapidly diagnose COVID-19 is being used around the world.

Based on type, the glucose monitoring segment is expected to be the most lucrative in the point of care diagnostics market. The considerable adoption of new technologies among academics and academia, the rising diabetic patient population base, and the growing preference for home glucose testing are all aspects that contribute to this segment's size.

Geographically, North America is expected to be the most lucrative region in the global point of care diagnostics market. With the rising incidence and prevalence of lifestyle diseases, the North American market is gaining traction. Furthermore, the presence of key players in the region, favorable government scenario, increased awareness of self-testing and home care products, and significant adoption of novel technologies are all expected to contribute significantly to the growth of the North American point of care diagnostics market.

Related Links:
Valuates Reports 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.